Form 8-K - Current report:
SEC Accession No. 0001213900-24-054715
Filing Date
2024-06-21
Accepted
2024-06-21 15:15:00
Documents
15
Period of Report
2024-06-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0208076-8k_bio.htm   iXBRL 8-K 26955
2 CONSENT RESOLUTION OF THE BOARD OF DIRECTORS ea020807601ex99-1_bio.htm EX-99.1 9704
3 INSIDER TRADING POLICY ea020807601ex99-2_bio.htm EX-99.2 47952
  Complete submission text file 0001213900-24-054715.txt   268747

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bioe-20240618.xsd EX-101.SCH 3033
5 XBRL LABEL FILE bioe-20240618_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE bioe-20240618_pre.xml EX-101.PRE 22371
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0208076-8k_bio_htm.xml XML 3445
Mailing Address 12 CHRYSLER UNIT B IRVINE CA 92618
Business Address 12 CHRYSLER UNIT B IRVINE CA 92618 949-706-9966
Bio Essence Corp (Filer) CIK: 0001723059 (see all company filings)

EIN.: 943349551 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-56263 | Film No.: 241059821
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)